Completed PHASE2 INTERVENTIONAL 2-arm NCT01124604

An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Osteoarthritis of the Knee or Low Back Pain

Sponsor: Janssen Pharmaceutical K.K.

Conditions Back Pain Low Back Pain Osteoarthritis, Knee Pain

Interventions Placebo Tapentadol Hydrochloride

Updated 7 times since 2017 Last updated: May 10, 2013 Started: Apr 30, 2010 Primary completion: Dec 31, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Back Pain and Low Back Pain and is currently completed. Janssen Pharmaceutical K.K. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Amagasaki, Japan , Chiba, Japan , Chikushi, Japan , Edogawa City, Japan , Fukuoka, Japan , Fukushima, Japan , Hiratsuka, Japan , Kawasaki, Japan , Kōtō City, Japan and 9 more locations